Ovarian Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
P
Recruiting
  • Advanced Malignancies
  • +4 more
  • Koto, Tokyo, Japan
    Japanese Foundation for Cancer Research
2021-10-07
Oct 7, 2021
N
Not yet recruiting
  • Breast Cancer
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-10-14
    Oct 14, 2021
    N
    Recruiting
    • Peritoneal Carcinomatosis
    • +4 more
    • Mitomycin C
    • +6 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2021-10-14
    Oct 14, 2021
    V
    Recruiting
    • Ovarian Cancer
    • Scottsdale, Arizona
    • +26 more
    2021-10-14
    Oct 14, 2021
    A
    Recruiting
    • Ovarian Cancer
    • OTL38
    • intraoperative imaging camera system
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    2021-10-08
    Oct 8, 2021
    P
    Recruiting
    • Non-small Cell Lung Cancer
    • +9 more
    • Little Rock, Arkansas
    • +50 more
    2021-10-14
    Oct 14, 2021
    N
    Active, not recruiting
    • Melanoma
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      2021-10-14
      Oct 14, 2021
      T
      Not yet recruiting
      • Ovarian Cancer
      • Wuhan, Hubei, China
        Tongji Hospital of Tongji Medical College, Huazhong University o
      2021-10-06
      Oct 6, 2021
      E
      Recruiting
      • Minimal Residual Disease
      • +11 more
      • ELI-002 2P
      • Duarte, California
      • +10 more
      2021-10-06
      Oct 6, 2021
      U
      Recruiting
      • Bile Duct Cancer
      • +8 more
      • Gainesville, Florida
        University of Florida
      2021-10-05
      Oct 5, 2021
      E
      Recruiting
      • Locally Advanced Solid Tumor
      • +16 more
      • Birmingham, Alabama
      • +26 more
      2021-10-13
      Oct 13, 2021
      T
      Recruiting
      • Ovarian Cancer
      • Tokyo, Japan
        Takeda Selected Site
      2021-10-12
      Oct 12, 2021
      M
      Completed
      • Ovarian Cancer
      • +2 more
      • Houston, Texas
        University of Texas MD Anderson Cancer Center
      2021-10-07
      Oct 7, 2021
      C
      Recruiting
      • HER2-positive Metastatic Breast Cancer
      • +3 more
      • Blood sample collection
      • Lille, France
        Centre Oscar Lambret
      2021-10-05
      Oct 5, 2021
      G
      Completed
      • Ovarian Cancer
      • Brussels, Belgium
      • +8 more
      2021-10-05
      Oct 5, 2021
      H
      Active, not recruiting
      • Ovarian Cancer
      • +5 more
      • Baseline Biopsy
      • +2 more
      • Tampa, Florida
        H. Lee Moffitt Cancer Center and Research Institute
      2021-10-11
      Oct 11, 2021
      A
      Completed
      • TNBC - Triple-Negative Breast Cancer
      • Ovarian Cancer
      • Scottsdale, Arizona
      • +26 more
      2021-10-08
      Oct 8, 2021
      S
      Recruiting
      • Ovarian Cancer
      • +2 more
      • Duarte, California
      • +8 more
      2021-10-07
      Oct 7, 2021
      N
      Recruiting
      • ER+ Breast Cancer
      • +18 more
      • Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
      • Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
      • Haifa, Israel
      • +3 more
      2021-10-03
      Oct 3, 2021